NovaBridge Biosciences
NBP
$4.26
-$0.01-0.23%
NASDAQ
| 06/30/2025 | 12/31/2024 | 06/30/2024 | 09/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -184.01% | -314.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -184.01% | -314.43% |
| Cost of Revenue | -- | -- | -- | -100.00% | -77.99% |
| Gross Profit | -- | -- | -- | -28.41% | -629.90% |
| SG&A Expenses | -- | -- | -- | -53.34% | -27.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | -56.33% | -36.96% |
| Operating Income | -- | -- | -- | 51.01% | 22.09% |
| Income Before Tax | -- | -- | -- | 60.37% | 17.96% |
| Income Tax Expenses | -- | -- | -- | 0.82% | 140.54% |
| Earnings from Continuing Operations | -- | -- | -- | 60.36% | 17.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | 41.74% | 8.36% |
| EBIT | -- | -- | -- | 51.01% | 22.09% |
| EBITDA | -- | -- | -- | 51.67% | 22.60% |
| EPS Basic | -- | -- | -- | 42.95% | 13.56% |
| Normalized Basic EPS | -- | -- | -- | 62.32% | 25.85% |
| EPS Diluted | -- | -- | -- | 42.95% | 13.59% |
| Normalized Diluted EPS | -- | -- | -- | 62.32% | 25.85% |
| Average Basic Shares Outstanding | -- | -- | -- | 2.09% | 5.92% |
| Average Diluted Shares Outstanding | -- | -- | -- | 2.09% | 5.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |